Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype
Latest Information Update: 16 Jul 2019
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 07 Aug 2018 Results (n=24) published in the Clinical Pharmacokinetics.
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Status changed from not yet recruiting to completed, as per results presented at the 68th Annual Meeting of the American Academy of Neurology.